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Conclusions: Only 38.6% of patients that died of prostate cancer 
received palliative RT to bone (PRTB) prior to death, but this 
increased overtime to 44% by 2015. It is difficult to know the 
proportions of prostate cancer patients that have indications for 
PRTB, and whether this utilization reflects appropriate access. 
This study shows that majority of patients that die of prostate 
cancer do so within a year of their first course of palliative RT to 
bone, and only a minority of patients are treated within four 
weeks of death. 
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Purpose: Many patients with cancer require home-based 
assistance which may be provided by a family or lay caregiver. 
Shorter inpatient hospital stays, limited home care resources, 
and a preference to die at home, result in unprecedented 
demands on these informal caregivers (IC). We sought to identify 
a questionnaire which can be used to characterize quality of life 
of those caring for a palliative oncology population. 
Methods and Materials: English publications describing 
instruments used to measure distress in IC of cancer patients 
were identified via literature search. Eligibility criteria included 
measurement of QOL during caregiving, prior to the patient’s 
death, unrelated to a specific procedure. Characteristics of 
instruments were summarized and factors associated with 
increased IC distress were tabulated 
Results: Sixteen questionnaires were identified measuring 
objective and/or subjective burden. Tools contained up to 53 
questions and required < 30 minutes for self-administration. 
Patient factors associated with increased IC burden included 
poor performance status, rapid clinical deterioration, and 
symptom severity. IC factors associated with increased burden 
included younger age, spousal relationship, female gender, 
lower education, preexisting financial strain, and lack of social 
supports. Of the tools reviewed, the Caregiver Quality of Life 
Index in Cancer (CQOLC) was selected for further study due to 
its ease of use and comprehensiveness. The CQOLC has been 
validated in IC of outpatients as well as in home hospice patients. 
Each of its 35 items maps to a specific domain which facilitates 
subsequent referral to support services. 
Conclusions: Future research will utilize the CQOLC to screen IC 
of patients referred to a dedicated palliative radiotherapy 
program. Additional items will explore potential correlates with 
reported burden. Early identification of vulnerable IC should 
facilitate delivery of appropriate support, minimizing the degree 
of distress experienced. 
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Purpose: The optimal dose for palliative whole brain 
radiotherapy (WBRT) continues to be debated. Common 
regimens include 20 Gy in five and 30 Gy in 10 fractions. We 
aimed to identify factors associated with WBRT dose schedules, 
hypothesizing that clinical prediction of survival (CPS) would 
influence prescribing practice. 
Methods and Materials: Demographic and clinicopathologic data 
were collected for consecutive patients with brain metastases 
receiving WBRT through a dedicated palliative radiation oncology 
clinic. At initial consultation, CPS were prospectively collected 
from treating radiation oncologists. Karnofsky Performance 
Status (KPS) and Mini-Mental State Examination (MMSE) were 
available for 88.6% and 75.1%, respectively. Dose fractionation 
was collected and summary statistics calculated. Parameters 
were assessed for association with five-fraction schedules using 
binary logistic regression, with odds ratios and 95% CI reported. 
Results: One hundred and ninety-three patients underwent 
WBRT (n = 102 from 2010-2012; n = 91 from 2013-2014); 38/193 
had 48 extracranial sites irradiated concurrently. 46.1% were 
male, mean age was 64.7 years (SD 11.6), and 63.7% had lung 
cancer. Median KPS was 70 (range 20-100) and median MMSE 
score was 27/30 (range 13-30). Median CPS and actual survival 
were 150 days (range 21-730d) and 96 days (range 11-1029d), 
respectively. 18.7% received WBRT within 30 days of death. 
78.2% (151/193) and 17.6% (34/193) received 5 and 10 fractions, 
respectively; 8/193 were prescribed other schedules. On 
multivariate analysis, patients with KPS ≤ 70 were 5.93 times 
more likely to have received 5 fractions (95% CI 2.51-14.1; p < 
0.0001). Those treated 2010-2012 were less likely to have 
received 5 fractions (OR 0.28; 95% CI 0.11-0.68; p = 0.005). CPS, 
age, gender, MMSE, histology, disease extent, and extracranial 
irradiation were not predictive of WBRT schedule. 
Conclusions: Patients treated with WBRT with KPS ≤ 70 and those 
treated more recently were more likely to receive five fractions. 
Oncologist CPS was not a statistically significant predictor of 
schedule in this cohort. 
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Purpose: Quality of life (QOL) can be compromised in patients 
with bone metastases. The use of validated QOL instruments is 
necessary to accurately measure QOL outcomes in this 
population. This study investigated the validity, reliability and 
responsiveness of the EORTC QLQ-BM22 module with the EORTC 
QLQ-C15-PAL instrument in bone metastases. 
Methods and Materials: The studied patients underwent 
palliative radiotherapy to bone metastases as part of the Phase 
III randomised NCIC CTG SC 23 trial. Multitrait scaling analysis 
was performed to determine convergent and divergent validity 
among the scales. Pearson coefficients were calculated to 
determine the correlation between the items of the two 
